Reverse phase high performance liquid chromatographic (HPLC) method for simultaneous determination of atorvastatin, ezetimibe and fenofibrate in commercial tablets

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 4, Issue 1, 2012, Pages 206-209

  Ajmera, Ankit ^a   Deshpande, Shrikalp ^b   Patel, Pranav ^a   Patel, Keyur ^a   Solanki, Sagar ^a   Rathod, Kinjal ^a  

^a Shri AK Raval Charitable Trust   (India)

^b K B Institute of Pharmacy   (India)

Author keywords

Atorvastatin calcium; Ezetimibe; Fenofibrate; Gradient; Photodiode array (PDA); Reverse phase HPLC

Indexed keywords

ACETONITRILE; ATORVASTATIN; EZETIMIBE; FENOFIBRATE; WATER;

ACCURACY; ARTICLE; COLUMN CHROMATOGRAPHY; DRUG DETERMINATION; DRUG ISOLATION; ELUTION; LIMIT OF DETECTION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ROOM TEMPERATURE; TABLET FORMULATION;

EID: 84855496803     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Remington - The science and practice of pharmacy, 21st ed. Lippincott Williams & Wilkins; 2006. p.1368.
2. Martindale -The complete drug reference, 32nd ed. Pharmaceutical Press 1; 1999. p.1268.
3. Sever PS, Poulter NR, Dahlof B, Wewdwl H. Different Time Course for Prevention of coronary and Stroke Events by Atorvastatin in the Anglo-Scanadinavian Cardiac Outcomes Trial- Lipid - Lowering Arm (ASCOT-LLA). Am J Cardiol 2005; 96: 39-44.
4. Newman C, Tsai J, Szarek M, Luo D, Gibson E. Comparative safety of Atorvastatin 80mg versus 10mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 2006; 97: 61-67.
5. The Indian Pharmacopoeia, Indian Pharmacopoeial Commission, India; 2007.
6. The British Pharmacopoeia, British Pharmacopoeial Commission, London; 2007.
7. Jamshidi A, Nateghi AR. HPTLC Determination of Atorvastatin in plasma. Chromatographia 2007; 65: 763-766.
8. Bahrami G. Mohammadi B, Mirzaeei S, Kiani A. Determination of Atorvastatin in human serum by reversed-phase high performance liquid chromatography with UV detection. J Chromatogr B 2005; 826: 41-45.
9. Erturk S, Aktas ES, Ersoy L, Ficicioglu S. J Pharm Biomed Anal 2003; 33: 1017-1023.
10. Mohammadia A, Rezanour N, Dogahehc MA, Bidkorbeh FG, Hashemb M, et al. J Chromatogr B 2007; 846: 215-221.
11. Panchal HJ, Suhagia BN, Patel NJ, Rathod IS, Patel BH. Simultaneous Estimation of Atorvastatin Calcium, Ramipril and Aspirin in capsule Dosage Form by RP-LC. Chromatographia 2009; 69: 91-95.
12. Kadav A, Vora DN. Stability indiacating UPLC method for simulatenous determination of Atorvastatin calcium, Fenofibrate and their degradation products in tablets. J Pharm Biomed Anal 2008; 48: 120-126.
13. Mazurek S, Szostak R. Quantification of atorvastatin calcium polymorph in tablets by FT-Raman spectroscopy. J. Pharm Biomed Anal 2009; 49: 168-172.
14. Skorda D, Kontoyannis CG. Identification and Quantitative determination of atorvastatin calcium polymorph in tablets by FT-Raman spectroscopy. Talanta 2008; 74: 1066-1070.
15. Kerzner B, Corbelli J, Sharp S, Lipka L, Melani L, et al. J cardiol 2003; 91: 418-424.
16. Melani L, Milla R, Hassman D, Lipetz R, Lipa L, et.al. Eur. Heart J 2003; 24: 717-728.
17. Sistla R, Tata VSSK, Kashyap YV, Chrasekar D, Diwan PV. J Pham Biomed Anal 2005; 39: 517-522.
18. Sonawanw SS, Shrikhedkar AA, Fursule RA, Surana SJ. Application of UV-Spectrophotometry and RP-HPLC for Simultaneous Determination of Atorvastatin Calcium and Ezetimibe in pharmaceutical dosage form. Eurasian Journal of analytical Chemistry 2006; 1: 31-41.
19. Kumar DA, Sujan DP, Vijayasree V, E Rao JVLNS. Simultaneuos Determination of Simvastatin and ezetimibe in tablets by HPLC. Journal of Chemistry 2009; 6: 541-544.
20. Singh S. Singh B, Bahuguna R, Wadhwa L, Saxena R. Stress degradation studies on ezetimibe and development of a validated stability-indicating HPLC assay. J pharm Biomedn Annal 2006; 41: 1037-1040.
21. Doshi AS, Kachhadia PK, Joshi HS. Validation of stability-indicating LC method for assay of Ezetimibe in tablets and for determination of content uniformity. Chromatographia 2008; 67: 137-142.
22. Oswald S, Scheuch E, Cascorbid I, Siegmund W. J Chromatogr B 2006; 830: 143-150.
23. Shuijun L, Gangyi L, Jingying J, Xiaochuan L, Chen Y. J Pharm Biomed Anal 2006; 40: 987-992.
24. United States Pharmacopoeia 32 (USP 32). United States Pharmacopoeia Convention; Rockville; 2009. p. 2351
25. Lacroix PM, Dawson BA, Sears RW, Black DB, Cyr TD, et al. Fenofibrate raw materials: HPLC methods for assay and purity and NMR method for purity. J Pharm Biomed Anal 1998; 18: 383-402.
26. El-Gindy A, Emara S, Mesbah MK, Hadad GM. Sprectophotometric and liquid chromatographic determination of Fenofibrate and vinpocetine and their hydrolysis products. Farmaco 2005; 60: 425-438.
27. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, et al. Additive beneficial effects of Fenofibrate combined with Atorvastatin in the treatment of combined hyperlypidemia. J Am Coll Cardiol 2005; 45: 1649-1653.
28. Famier M. Freeman MW, Macdonell G, Perevozskaya I, Davies MJ, et al. Efficacy and safety of the coadministeation of Ezetimibe with Fenofibrate in patients with mixed hyperlipidemia. Eur Heart J 2005; 26: 897-905.
29. www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality?Q2_R1/Step4/Q2_R1_Guideline